ALFA-INTERFERONE ADIUVANTE NEL CARCINOMA RENALE AD ALTO RISCHIO DI RICADUTA. STUDIO PILOTA MULTICENTRICO

Translated title of the contribution: Adjuvant alpha-interferon in renal cell carcinoma at high-risk of relapse. A multicenter pilot study

G. Pizzocaro, L. Piva, M. Faustini, N. Nicolai, R. Salvioni, R. Pisani, A. Maggioni, A. Mandressi, E. Dormia, S. Minervini, S. Cosciani Cunico, A. Cozzoli, F. Catanzaro, A. Ghislandi

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-eight consecutive patients submitted to radical nephrectomy for Robinson's stage II - III renal cell carcinoma underwent adjuvant recombinant a-2b interferon, 5 MUI s.c. 3 times a week, for 6 consecutive months. Home-feasibility of this therapy resulted easy. The most frequent acute (flu-like syndrome) and late (myalgia, fatigue, anorexia) side effects did not affect normal daily life of patients. Eight (28.5%) patients had WHO grade ≤ 2 biochemical and hematological toxicity, that normalized after a reduction or a temporarily suspension of therapy. Twenty-seven patients were evaluable for response. Out of these, 7 (26%) relapsed after a 16 months median follow-up.

Translated title of the contributionAdjuvant alpha-interferon in renal cell carcinoma at high-risk of relapse. A multicenter pilot study
Original languageItalian
Pages (from-to)173-176
Number of pages4
JournalArchivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell"Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences
Volume65
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Adjuvant alpha-interferon in renal cell carcinoma at high-risk of relapse. A multicenter pilot study'. Together they form a unique fingerprint.

Cite this